These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17689027)

  • 1. Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency.
    Davidson SE; Trotti A; Ataman OU; Seong J; Lau FN; da Motta NW; Jeremic B
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1218-21. PubMed ID: 17689027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation.
    Chen Y; Trotti A; Coleman CN; Machtay M; Mirimanoff RO; Hay J; O'brien PC; El-Gueddari B; Salvajoli JV; Jeremic B
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1442-51. PubMed ID: 16414207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety in radiation oncology: the role of international initiatives by the International Atomic Energy Agency.
    Abdel-Wahab M; Rosenblatt E; Holmberg O; Meghzifene A
    J Am Coll Radiol; 2011 Nov; 8(11):789-94. PubMed ID: 22051464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adverse event capture and management system for cancer studies.
    Lencioni A; Hutchins L; Annis S; Chen W; Ermisoglu E; Feng Z; Mack K; Simpson K; Lane C; Topaloglu U
    BMC Bioinformatics; 2015; 16 Suppl 13(Suppl 13):S6. PubMed ID: 26424052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians.
    Reeve BB; Withycombe JS; Baker JN; Hooke MC; Lyons JC; Mowbray C; Wang J; Freyer DR; Joffe S; Sung L; Tomlinson D; Gold SH; Hinds PS
    Pediatr Blood Cancer; 2013 Jul; 60(7):1231-6. PubMed ID: 23335328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
    J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Kluetz PG; Chingos DT; Basch EM; Mitchell SA
    Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IAEA support to medical physics in nuclear medicine.
    Meghzifene A; Sgouros G
    Semin Nucl Med; 2013 May; 43(3):181-7. PubMed ID: 23561455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes and the evolution of adverse event reporting in oncology.
    Trotti A; Colevas AD; Setser A; Basch E
    J Clin Oncol; 2007 Nov; 25(32):5121-7. PubMed ID: 17991931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
    Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
    Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment.
    Lam KO; Lee AW; Ng WT; Hopkins KI
    Chin Clin Oncol; 2016 Apr; 5(2):27. PubMed ID: 27121887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twinning partnerships through International Atomic Energy Agency (IAEA) to improve radiotherapy in common paediatric cancers in low- and mid-income countries.
    Salminen E; Anacak Y; Laskar S; Kortmann RD; Raslawski E; Stevens G; Ribeiro RC
    Radiother Oncol; 2009 Nov; 93(2):368-71. PubMed ID: 19748141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse event reporting in publications compared with sponsor database for cancer clinical trials.
    Scharf O; Colevas AD
    J Clin Oncol; 2006 Aug; 24(24):3933-8. PubMed ID: 16921045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
    Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
    Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of and adherence to CTCAE v3.0 in cancer clinical trial publications.
    Zhang S; Chen Q; Wang Q
    Oncotarget; 2016 Oct; 7(40):65577-65588. PubMed ID: 27564109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and misuse of common terminology criteria for adverse events in cancer clinical trials.
    Zhang S; Liang F; Tannock I
    BMC Cancer; 2016 Jul; 16():392. PubMed ID: 27377548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrater Reliability in Toxicity Identification: Limitations of Current Standards.
    Fairchild AT; Tanksley JP; Tenenbaum JD; Palta M; Hong JC
    Int J Radiat Oncol Biol Phys; 2020 Aug; 107(5):996-1000. PubMed ID: 32371073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.